

ACIP Rotavirus Vaccines Working Group: Overview

Lance Chilton, MD
Chair, ACIP Rotavirus Vaccines Working Group
October 25, 2007



DEPARTMENT OF HEALTH AND HUMAN SERVICES



ACIP Rotavirus Vaccines Working Group

- James Alexander
- William Atkinson
- Angela Calcular
- Lance Chilton
- Margaret Cortese
- Penny Dennehy
- Geoff Evans
- Paul Gargiullo
- Roger Glass
- Stanley Grogg
- Penina Haber
- Hector Izurieta
- Sam Katz
- Paul Kitsutani
- Thomas Koinis
- Susan Lett
- Ed Marcuse
- John Modlin
- Julie Morita
- Trudy Murphy
- Umesh Parashar
- Manish Patel
- Larry Pickering
- Steve Rosenthal
- Jane Seward
- Rosemary Tiernan
- John Treanor
- Greg Wallace
- Marc-Alain Widdowson

Rotavirus Vaccines 2006/7

Live, oral

- Pentavalent human-bovine reassortant rotavirus vaccine (PRV): RotaTeq® (Merck)
 - Licensed Feb 2006
 - ACIP recommendations Feb 2006
 - Routine infant vaccination at ages 2, 4, 6 months
- Attenuated monovalent human rotavirus vaccine (HRV), Rotarix® (GSK)
 - BLA submitted to FDA June 2007
 - Studied as two-dose series at ages 2, 4 months

Rotavirus Vaccines Working Group Plans

- Review data on HRV (Rotarix®)
- Propose recommendations for ACIP to consider, should HRV become licensed
- Continue to review post-marketing data on PRV (RotaTeq®)
 - ISO, FDA

Rotavirus Vaccines Working Group Plans

■ Present to ACIP

- February 2008: Information, discussion, draft recommendations
 - HRV (Rotarix®)
 - Address issues with two different vaccines
- June 2008: Possible ACIP vote on proposed recommendations (if HRV licensed)

Presentation to ACIP on Rotavirus Vaccines October 25, 2007

- Information on HRV (Rotarix®):
presented by GSK
 - Efficacy, safety, co-administration
 - Questions/answers
- Update on PRV (RotaTeq®)
 - Coverage estimates, adherence to age recommendations: presented by CDC
 - Update safety monitoring: presented by ISO